Herpes Labialis Treatment Market

Author: Reports and Insights

The global herpes labialis treatment market in 2020 is estimated for more than US$ 242.9 Mn and expected to reach a value of US$ 379.3 Mn by 2028 with a significant CAGR of 5.7%

 

Reports and Insights (R&I) has published a new report titled, Herpes Labialis Treatment Market: Opportunity Analysis and Future Assessment 2020 to 2028

Global Herpes Labialis Treatment Market, by Type (Acyclovir, Valacyclovir, Famciclovir, Penciclovir, and Docosanol), by Route Of Administration (Oral, Topical, and Combination), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drug Stores, and Online Pharmacies), and By Region (North America, Europe, Asia Pacific, Latin America, Middle East, & Africa) is expected to grow at a significant CAGR for the period between 2020 and 2028.

The global herpes labialis treatment market in 2020 is estimated for more than US$ 242.9 Mn and expected to reach a value of US$ 379.3 Mn by 2028 with a significant CAGR of 5.7%

As per the report, increasing the occurrence of viral infection and the growing investments in R&D activities propels the market growth. Besides, the strategic collaboration between the key players including mergers and acquisitions for the expansion of their product portfolio is also expected to expand the business growth during the forecast years.

Increasing investments for renovating the existing drugs coupled with the invention of new and efficient drugs in examining the clinical efficacy of the drug is another major growth affecting factor increasing the demand for herpes labialis treatment.

Other factors like the soaring penetration of generics, regular transformations in disease treatment, and frequent product innovation are also expected to offer growth opportunities for herpes labialis treatment market during the next decade.

Furthermore, Reports and Insights (R&I) Study also unleashed the facts revealed by the American Sexual Health Association, listing that more than 50% of the American adults suffer from oral herpes, which is also commonly known as cold sores or fever blisters. Most of the oral herpes condition is due to the HSV-1 infection.

On the other hand, one among the eight people aging in between 14 years to 49 years in U. S. suffers from HSV-2 infection. However, many such cases remain unnoticed owing to too mild symptoms.

R&I Study identifies some of the key participating players in the herpes labialis treatment market globally are Abbott Laboratories, Dr. Reddy’s Laboratories, GlaxoSmithKline plc., Mylan N.V., Novartis AG, Pfizer Inc., Sun Pharmaceuticals Industries Ltd., Teva Pharmaceuticals, Inc., and Valeant Pharmaceuticals International Inc.

About Reports and Insights:

Reports and Insights (R&I) is committed to provide deep insights that serve as a creative tool for the client that enables it to perform confidently in the market. At R&I we adhere to the client's needs and regularly ponder to bring out more valuable and real outcomes for our customers. We are equipped with a strategically enhanced group of researchers and analysts that redefines and stabilizes the business polarity in different categorical dimensions of the market.

Contact Us:

Reports and Insights (R&I)

Tel: +1-(281)-619-8646

For Sales Queries: sales@reportsandinsights.com

For New Topics and Other Info: info@reportsandinsights.com